{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:07:03Z","timestamp":1770408423372,"version":"3.49.0"},"reference-count":111,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Cardiovascular Therapy"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1586\/14779072.2.4.473","type":"journal-article","created":{"date-parts":[[2005,1,13]],"date-time":"2005-01-13T08:28:53Z","timestamp":1105604933000},"page":"473-483","source":"Crossref","is-referenced-by-count":17,"title":["Losartan in diabetic nephropathy"],"prefix":"10.1586","volume":"2","author":[{"given":"Norberto","family":"Perico","sequence":"first","affiliation":[{"name":"Department of Medicine and Transplantation, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy. perico@marionegri.it"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Transplantation, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy. ruggenenti@marionegri.it"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Transplantation, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy. gremuzzi@marionegri.it"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V12122753"},{"key":"e_1_2_1_6_1","doi-asserted-by":"crossref","first-page":"S37\u2014S40","DOI":"10.1681\/ASN.V13suppl_1s37","article-title":"Maintenance dialysis population dynamics: current trends and long-term implications","volume":"13","author":"Lysaght MJ","year":"2002","unstructured":"Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J. Am. Soc. NephroL 13, S37\u2014S40 (2002).","journal-title":"J. Am. Soc. NephroL"},{"key":"e_1_2_1_7_1","unstructured":"\u2022Demonstrates that the total cumulative cost for renal replacement therapy in the next decade will exceed US$1 trillion worldwide."},{"key":"e_1_2_1_8_1","unstructured":"Ansell D Feest T Byrne C. UK Renal Registry Report 1999. Ansell D Feest T (Eds) UK Renal Registry Bristol UK (1999)."},{"key":"e_1_2_1_9_1","first-page":"1557","article-title":"End stage renal disease in Canada: prevalence projections to 2005","volume":"160","author":"Schaubel D","year":"1999","unstructured":"Schaubel D, Morrison H, Desmeules M et al End stage renal disease in Canada: prevalence projections to 2005. Can. Med Assoc. J. 160, 1557\u20131563 (1999).","journal-title":"Can. Med Assoc. J"},{"key":"e_1_2_1_10_1","author":"US Renal Data System","year":"2000","unstructured":"US Renal Data System. Excerpts from the USRDS annual data report. Am. J. Kidney Dis. 36(Suppl.), S1\u2014S239 (2000).","journal-title":"Am. J. Kidney Dis"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.49.9.1399"},{"key":"e_1_2_1_12_1","first-page":"95","author":"National Diabetes Data Group","year":"1995","unstructured":"National Diabetes Data Group: Diabetes in America, 2nd Edition. The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, NIH Publication, ND, USA 95\u20131468 (1995).","journal-title":"Diabetes in America"},{"key":"e_1_2_1_13_1","unstructured":"\u2022Analysis of the risk of overt nephropathy in Type 1 and 2 diabetic patients."},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/08860228509088195"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1976.03270170027020"},{"key":"e_1_2_1_16_1","author":"Parving H-H","year":"2000","unstructured":"Parving H-H, Osterby R, Ritz E. Diabetic nephropathy. In: The Kidney. Brenner BM (Ed.), WB Saunders, PA, USA (2000).","journal-title":"The Kidney"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365517609055274"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00253407"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.294.6588.1651"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.11.1303"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.299.6693.230"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)92462-5"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011489"},{"key":"e_1_2_1_25_1","unstructured":"\u2022\u2022Demonstrates that an angiotensin (AT)-1 receptor blocker reduces the incidence of overt nephropathy in hypertensive microalbuminuric Type 2 diabetic patients."},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"e_1_2_1_27_1","unstructured":"\u2022\u2022Demonstrates that an ATi-receptorantagonist is more renoprotective than a dihydropiridinic calcium channel blocker in Type 2 diabetic patients with overt nephropathy."},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"e_1_2_1_29_1","unstructured":"\u2022\u2022 ATi-receptor blockade with losartan is more renoprotective than conventional antihypertensive therapy in patients with Type 2 diabetes and overt nephropathy."},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00797.x"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811123392007"},{"key":"e_1_2_1_32_1","first-page":"670A","volume":"12","author":"Abbate M","year":"2001","unstructured":"Abbate M, Zoja C, Morigi M et al. In progressive nephropathy, exuberant podocyte TGFB activates a prosclerosis phenotype in mesangial cells. J. Am. Soc. Nephrol. 12, (2001) (Abstract 670A).","journal-title":"J. Am. Soc. Nephrol"},{"key":"e_1_2_1_33_1","doi-asserted-by":"crossref","first-page":"S36\u2014S41","DOI":"10.1097\/01.ASN.0000068626.23485.E0","article-title":"Remuzzi G. Proteinuria and phenotypic change of proximal tubular cells","volume":"14","author":"Zoja C","year":"2003","unstructured":"Zoja C, Morigi M, Remuzzi G. Proteinuria and phenotypic change of proximal tubular cells. J. Am. Soc. Nephrol. 14, S36\u2014S41 (2003).","journal-title":"J. Am. Soc. Nephrol"},{"issue":"2","key":"e_1_2_1_34_1","author":"Eddy AA","year":"2001","unstructured":"Eddy AA. Role of cellular infiltrates in response to proteinuria. Am. J. Kidney Dis. 37\\(Suppl. 2), S25\u2014S29 (2001).","journal-title":"Am. J. Kidney Dis"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00048.x"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00874.x"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00868.x"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.42.5.715"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00885.x"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-10-199511150-00003"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04433-X"},{"issue":"4","key":"e_1_2_1_43_1","volume":"45","author":"Apperloo AJ","year":"1994","unstructured":"Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with nondiabetic renal disease. Kidney Int. 45\\(Suppl. 4), S174\u2014S178 (1994).","journal-title":"Kidney Int"},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.059002702.x"},{"key":"e_1_2_1_45_1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0140-6736(99)90122-8","article-title":"de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion","volume":"354","author":"de Jong PE","year":"1999","unstructured":"de Jong PE, Navis GJ, de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 354, 352\u2013353 (1999).","journal-title":"Lancet"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00033.x"},{"issue":"3","key":"e_1_2_1_47_1","volume":"20","author":"Aros C","year":"2002","unstructured":"Aros C, Remuzzi G. The renin\u2014angiotensin system in progression, remission and regression of chronic nephropathies. J. Hypertens. 20\\(Suppl. 3), S45\u2014S53 (2002).","journal-title":"J. Hypertens"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.61.4.531"},{"key":"e_1_2_1_49_1","doi-asserted-by":"crossref","unstructured":"Lapinski R Perico N Remuzzi A Sangalli F Benigni A Remuzzi G. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J. Am. Soc. NephroL 7 653\u2013660 (1996).","DOI":"10.1681\/ASN.V75653"},{"key":"e_1_2_1_50_1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ki.1994.47","article-title":"A role for podocytes to counteract capillary wall distension","volume":"45","author":"Kritz W","year":"1994","unstructured":"Kritz W Hackenthal E, Nobiling R, Sakai T, Elger M. A role for podocytes to counteract capillary wall distension. Kidney Int. 45,369\u2013376 (1994).","journal-title":"Kidney Int"},{"key":"e_1_2_1_51_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1523-1755.2004.00362.x","article-title":"Activation of a local angiotensin system in podocytes by mechanical strain","volume":"65","author":"Duvarsula RV","year":"2004","unstructured":"Duvarsula RV, Petermann AT, Hiromura K et al Activation of a local angiotensin system in podocytes by mechanical strain. Kidney Int. 65,30\u201339 (2004).","journal-title":"Kidney Int"},{"key":"e_1_2_1_52_1","first-page":"568A","article-title":"Daniels BS. Angiotensin II induces actin polymerization within glomerular filtration barrier: possible role in the local regulation of ultrafiltration","volume":"3","author":"Shake JG","year":"1992","unstructured":"Shake JG, Brandt RC, Daniels BS. Angiotensin II induces actin polymerization within glomerular filtration barrier: possible role in the local regulation of ultrafiltration. J. Am. Soc. Nephrol. 3,568A (1992).","journal-title":"J. Am. Soc. Nephrol"},{"key":"e_1_2_1_53_1","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1172\/JCI119467","article-title":"Angiotensin II depolarizes podocytes in the intact glomerulus of the rat","volume":"99","author":"Gloy J","year":"1997","unstructured":"Gloy J, Henger A, Fischer K-G et al. Angiotensin II depolarizes podocytes in the intact glomerulus of the rat. J. Clin. Invest. 99,2772\u20132781 (1997).","journal-title":"J. Clin. Invest"},{"key":"e_1_2_1_54_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ndt\/15.suppl_6.61","author":"Wolf G","year":"2000","unstructured":"Wolf G. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol. Died Transplant. 15(Suppl. 6), 61\u201363 (2000).","journal-title":"Nephrol. Died Transplant"},{"key":"e_1_2_1_55_1","first-page":"448","article-title":"E Renal tubular hypertrophy induced by angiotensin II","volume":"17","author":"Wolf G","year":"1997","unstructured":"Wolf G, Ziyadeh E Renal tubular hypertrophy induced by angiotensin II. Seminar NephroL 17,448\u2013454 (1997).","journal-title":"Seminar NephroL"},{"key":"e_1_2_1_56_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1525-1381.1999.99117.x","article-title":"Stahl R. Angiotensin II induces ot3 (IV) collagen expression in cultured urine proximal tubular cells","volume":"11","author":"Wolf G","year":"1999","unstructured":"Wolf G, Kalluri R, Ziyadeh F, Neilson E, Stahl R. Angiotensin II induces ot3 (IV) collagen expression in cultured urine proximal tubular cells. Proc. Assoc. Am. Physic. 11,357\u2013364(1999).","journal-title":"Proc. Assoc. Am. Physic"},{"key":"e_1_2_1_57_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000025911","article-title":"Interstitial pathomechanisms underlying progressive tubulointerstitial damage","volume":"22","author":"Strutz F","year":"1999","unstructured":"Strutz F, Muller GA. Interstitial pathomechanisms underlying progressive tubulointerstitial damage. Kidney Blood Press. Res. 22,71\u201380 (1999).","journal-title":"Kidney Blood Press. Res"},{"key":"e_1_2_1_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.150"},{"key":"e_1_2_1_59_1","first-page":"899","article-title":"Relationship among altered glomerular barrier permselectivity, angiotensin II and mesangial uptake of macromolecules","volume":"52","author":"Keane WF","year":"1985","unstructured":"Keane WF, Rai JL. Relationship among altered glomerular barrier permselectivity, angiotensin II and mesangial uptake of macromolecules. Lab. Invest. 52,899\u2013604 (1985).","journal-title":"Lab. Invest"},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.82"},{"key":"e_1_2_1_61_1","first-page":"F563\u2014F574","article-title":"Early role of Fsp 1 in epithelial-mesenchymal transformation","volume":"273","author":"Okada H","year":"1997","unstructured":"Okada H, Danoff T, Kalluri R, Neilson E. Early role of Fsp 1 in epithelial-mesenchymal transformation. Am. J. Physiol. 273, F563\u2014F574 (1997).","journal-title":"Am. J. Physiol"},{"key":"e_1_2_1_62_1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/01.HYP.17.4.480","article-title":"Nantel F, D'Orleans-Juste P, Regoli D. DuP 753 is a specific antagonist for the angiotensin receptor","volume":"14","author":"Rhaleb NE","year":"1991","unstructured":"Rhaleb NE, Rouissi N, Nantel F, D'Orleans-Juste P, Regoli D. DuP 753 is a specific antagonist for the angiotensin receptor. Hypertension 14,480\u2013484 (1991).","journal-title":"Hypertension"},{"key":"e_1_2_1_63_1","unstructured":"\u2022Summary of the ATi-receptor-blockade properties of losartan."},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200016030-00006"},{"issue":"1","key":"e_1_2_1_65_1","volume":"13","author":"Sica DA","year":"1995","unstructured":"Sica DA, Lo MW, Shaw WC et al The pharmacokinetics of losartan in renal insufficiency. J. Hypertens. 13\\(Suppl. 1), S49\u2014S52 (1995).","journal-title":"J. Hypertens"},{"key":"e_1_2_1_66_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200038060-00005"},{"key":"e_1_2_1_67_1","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2165\/00003495-199651050-00008","article-title":"Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension","volume":"51","author":"Ooak KL","year":"1996","unstructured":"Ooak KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 51,820\u2013845 (1996).","journal-title":"Drugs"},{"key":"e_1_2_1_68_1","unstructured":"Merck & Co. Cozaar product monograph. (2001)."},{"key":"e_1_2_1_69_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1042\/cs1000013","article-title":"\u00b0Driscoll 0, Stanton K et al. Losartan, an angiotensin Type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes","volume":"100","author":"Cheetman C","year":"2001","unstructured":"Cheetman C, \u00b0Driscoll 0, Stanton K et al. Losartan, an angiotensin Type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. Clin. Sci. 100,13\u201317 (2001).","journal-title":"Clin. Sci"},{"key":"e_1_2_1_70_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-3-200308050-00006"},{"key":"e_1_2_1_71_1","unstructured":"\u2022\u2022Losartan is more effective in hypertensivepatients than atenolol in preventing cardiovascular morbidity and death independent of blood pressure reduction."},{"key":"e_1_2_1_72_1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0009-9236(01)26448-0","article-title":"Losartan attenuates symptomatic and hormonal responses to hypoglycemia in humans","volume":"70","author":"Deininger E","year":"2001","unstructured":"Deininger E, Oltmanns KM, Wellhoener P et al. Losartan attenuates symptomatic and hormonal responses to hypoglycemia in humans. Clin. PharmacoL Ther 70, 362\u2013369 (2001).","journal-title":"Clin. PharmacoL Ther"},{"key":"e_1_2_1_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/12.1.19"},{"key":"e_1_2_1_74_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00224.x"},{"key":"e_1_2_1_75_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/dmrr.255","article-title":"Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in Type 2 diabetic patients with microalbuminuria","volume":"28","author":"Tan KC","year":"2002","unstructured":"Tan KC, Chow WS, Ai VH et al. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in Type 2 diabetic patients with microalbuminuria. Diabetes Metab. Res. Rev. 28,71\u201376 (2002).","journal-title":"Diabetes Metab. Res. Rev"},{"key":"e_1_2_1_76_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200204000-00030"},{"key":"e_1_2_1_77_1","doi-asserted-by":"crossref","unstructured":"Zandbergen AAM Baggen MGA Lamberts SWJ Bootsma AH de Zeeuw D Ouwendijk RJT. Effect of losartan on microalbuminuria in normotensive patients with Type 2 diabetes mellitus. Ann. Intern. Med. 139 90\u201396 (2003).","DOI":"10.7326\/0003-4819-139-2-200307150-00008"},{"key":"e_1_2_1_78_1","unstructured":"\u2022\u2022Provides evidence of the efficacy oflosartan in reducing albumin excretion rate in microalbuminuric normotensive patients with Type 2 diabetes."},{"issue":"2","key":"e_1_2_1_79_1","volume":"13","author":"Arteaga J","year":"2000","unstructured":"Arteaga J, Petrina E, Anda E et al. The antiproteinuric effect of enalapril is potentiated by losartan in normotensive patients with diabetic nephropathy. Am. J. Hypertens. 13\\(Pt 2), 117 (2000).","journal-title":"Am. J. Hypertens"},{"issue":"1","key":"e_1_2_1_80_1","volume":"44","author":"Yokota C","year":"2001","unstructured":"Yokota C, Kawai K, Okuda Y et al. Combination of AT1RB and ACE-I has a synergic effect on the reduction of microalbuminuria in Type 2 diabetic patients. Diabetologia 44\\(Supp1.1), 276 (2001).","journal-title":"Diabetologia"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/18.2.293"},{"key":"e_1_2_1_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.4.771"},{"key":"e_1_2_1_83_1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1523-1755.2000.00880.x","article-title":"Pawing H-H. Renoprotective effects of angiotensin II receptor blockade in Type 1 diabetic patients with diabetic nephropathy","volume":"57","author":"Andersen S","year":"2000","unstructured":"Andersen S, Tarnow L, Rossing P, Hansen BY, Pawing H-H. Renoprotective effects of angiotensin II receptor blockade in Type 1 diabetic patients with diabetic nephropathy. Kidney Int. 57,601\u2013606 (2000).","journal-title":"Kidney Int"},{"key":"e_1_2_1_84_1","unstructured":"\u2022\u2022Short-term cross-over study carried out inType 1 diabetic patients with persistent albuminuria demonstrates that losartan and angiotensin-converting enzyme inhibition have similar beneficial effect on albumin excretion rate."},{"key":"e_1_2_1_85_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semnephrol.2003.11.003","article-title":"Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points","volume":"24","author":"Parving H-H","year":"2004","unstructured":"Parving H-H, Andersen S, Jacobsen P et al. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Seminar NephroL 24,147\u2013157 (2004).","journal-title":"Seminar NephroL"},{"key":"e_1_2_1_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.8.1413"},{"key":"e_1_2_1_87_1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/bmj.313.7057.591","article-title":"Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow-up study","volume":"313","author":"Pawing H-H","year":"1996","unstructured":"Pawing H-H, Jacobsen P, Tarnow L et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow-up study. Br. Med. J. 313,591\u2013594 (1996).","journal-title":"Br. Med. J"},{"key":"e_1_2_1_88_1","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/j.1523-1755.1998.00847.x","volume":"53","author":"Jacobsen E Rossing K, Rossing P et al Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy","year":"1998","unstructured":"Jacobsen E Rossing K, Rossing P et al Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int-. 53, 1002\u20131006 (1998).","journal-title":"Kidney Int-"},{"key":"e_1_2_1_89_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.47.9.1507"},{"key":"e_1_2_1_90_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000092139.19587.51"},{"key":"e_1_2_1_91_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.5.1501"},{"key":"e_1_2_1_92_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00410.x"},{"key":"e_1_2_1_93_1","unstructured":"\u2022Indicates that losartan offers renoprotection independently of ACE insertion\/deletion genotype in albuminuric hypertensive Type 1 diabetic patients."},{"issue":"45","key":"e_1_2_1_94_1","author":"Lebovitz HE","year":"1994","unstructured":"Lebovitz HE, Wiegmann TB, Cnaan A et al Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int. (Suppl. 45), S150\u2014S155 (1994).","journal-title":"Kidney Int"},{"key":"e_1_2_1_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.480"},{"key":"e_1_2_1_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"e_1_2_1_97_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.46.7.1182"},{"key":"e_1_2_1_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000732"},{"key":"e_1_2_1_99_1","volume":"23","author":"Estacio RO","year":"2000","unstructured":"Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and Type 2 diabetes. Diabetes Care 23(Suppl. 2), 5B54-5B64 (2000).","journal-title":"Diabetes Care"},{"key":"e_1_2_1_100_1","author":"Merck & Co. Inc. FDA Advisory Committee recommends approval for Cozaar to delay progression of renal disease in Type","year":"2002","unstructured":"Merck & Co. Inc. FDA Advisory Committee recommends approval for Cozaar to delay progression of renal disease in Type 2 diabetic patients with proteinuria. Media Release 12, (2002).","journal-title":"Media Release"},{"key":"e_1_2_1_101_1","volume":"25","author":"American Diabetes Association","year":"2002","unstructured":"American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Carr 25(Suppl. 1), S33\u2014S49 (2002).","journal-title":"Diabetes Carr"},{"key":"e_1_2_1_102_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.683"},{"key":"e_1_2_1_103_1","doi-asserted-by":"crossref","unstructured":"Zatz R Dunn BR Meyer TW Anderson S Rennke HG Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 77 1925-1930 (1986).","DOI":"10.1172\/JCI112521"},{"key":"e_1_2_1_104_1","doi-asserted-by":"crossref","unstructured":"Remuzzi A Perico N Amuchastegui CS et al Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J. Am. Soc. 1Vephrol 4 40-49 (1993).","DOI":"10.1681\/ASN.V4140"},{"key":"e_1_2_1_105_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-2-200107170-00007"},{"key":"e_1_2_1_106_1","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1046\/j.1523-1755.2001.00020.x","article-title":"Diabetic nephropathy: prevention and treatment","volume":"60","author":"Pawing H-H","year":"2001","unstructured":"Pawing H-H. Diabetic nephropathy: prevention and treatment. Kidney Int. 60, 2041\u20132055 (2001).","journal-title":"Kidney Int"},{"key":"e_1_2_1_107_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.055003984.x"},{"key":"e_1_2_1_108_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.4.874"},{"key":"e_1_2_1_109_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V12122832"},{"key":"e_1_2_1_110_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000042343.03375.1B"},{"issue":"2","key":"e_1_2_1_111_1","volume":"51","author":"Buckalew V","year":"2002","unstructured":"Buckalew V, Martinez F, Altamirano J, Roniker J, Kleiman J, Krause S. The selective aldosterone blocker eplerenone is effective as monotherapy or adjunctive therapy in diabetic hypertensive with microalbuminuria. Diabetes 51\\(Suppl. 2), A38 (2002).","journal-title":"Diabetes"},{"key":"e_1_2_1_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04728-0"},{"key":"e_1_2_1_113_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00067.x"},{"key":"e_1_2_1_114_1","first-page":"153","article-title":"Beneficial effects of water-based exercise in patients with chronic kidney disease","volume":"26","author":"Pechter U","year":"2003","unstructured":"Pechter U, Ots M, Mesikepp S, Zilmer K et al Beneficial effects of water-based exercise in patients with chronic kidney disease. Int. J. Rehabil Res. 26,153\u2013156 (2003).","journal-title":"Int. J. Rehabil Res"},{"key":"e_1_2_2_2_1","unstructured":"Statistical review and evaluation \u2014 Cozaar\u00ae (Lozartan). NDA 20\u2013386 www.fda.gov\/ohrms\/dockets\/ac\/02\/briefing\/3 84961_04_statistical%20review%20addendu m.htm ical%20review.pdf (Accessed June 2004)"}],"container-title":["Expert Review of Cardiovascular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14779072.2.4.473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T09:14:16Z","timestamp":1770369256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14779072.2.4.473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":111,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1586\/14779072.2.4.473"],"URL":"https:\/\/doi.org\/10.1586\/14779072.2.4.473","relation":{},"ISSN":["1477-9072","1744-8344"],"issn-type":[{"value":"1477-9072","type":"print"},{"value":"1744-8344","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}